BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AUTX-703 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AUTX-703\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06846606-3021@assetmemo.bio
DTSTAMP:20261121T005447Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:AUTX-703: Phase 1 readout est. (NCT06846606)
DESCRIPTION:AUTX-703\, phase 1\, Acute Myeloid Leukemia.\nStudy: Phase 1 St
 udy of AUTX-703 in Relapsed/Refractory AML and MDS\nEstimated primary comp
 letion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/a
 utx-703#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06846606
URL:https://assetmemo.bio/drug/autx-703#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
